STAT+: AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.
Click here to view original post